A Phase II Study of Two Induction Courses of Bacillus Calmette-Guerin to Treat High-Risk Superficial Bladder Cancer

Full Title

Phase II study to evaluate the response of two induction courses (12 intravesical instillations) of Bacillus Calmette-Guérin (BCG) for high risk superficial bladder cancer


Bacillus Calmette-Guerin (BCG) therapy delivered directed into the bladder is highly effective for treating high-risk bladder cancer that has not grown into the muscle wall. The cancer occurs within a year in up to half of patients, however, and within five years in as many as 90 percent.

Patients typically receive one initial course of BCG treatment. In this study, researchers are assessing the safety and effectiveness of two induction course of BCG treatment, given three to four weeks apart, with the hope that this approach is more effective for reducing the risk of cancer recurrence than one course of BCG.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have bladder cancer that has not grown into the muscle wall and is determined to have a high risk of coming back after therapy.
  • For patients who had prior BCG or chemotherapy for bladder cancer, at least one year must have passed between completion of treatment and entry into the study.
  • Patients may not currently be undergoing or planning to undergo radiation therapy for bladder cancer.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Harry Herr at 646-422-4411.